Asset
INSULIN HUMAN
MannKind Corporation Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02527265 | phase2 | completed | 2017-09-28 | 2020-03-17 | Mannkind Corporation | Afrezza Safety and Pharmacokinetics Study in Pediatric Patients |
| NCT04974528 | phase3 | completed | 2021-09-29 | 2024-10-03 | Mannkind Corporation | Afrezza® INHALE-1 Study in Pediatrics |
| NCT05904743 | phase4 | completed | 2023-07-07 | 2024-03-26 | Mannkind Corporation | INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 022472 | BLA | Mannkind Corporation |
Marketed products (3)
- AFREZZA
- AFREZZA
- AFREZZA